Huber Financial Advisors LLC cut its holdings in Celgene Co. (NASDAQ:CELG) by 78.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,000 shares of the biopharmaceutical company’s stock after selling 10,860 shares during the period. Huber Financial Advisors LLC’s holdings in Celgene were worth $283,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in CELG. BlackRock Inc. lifted its holdings in shares of Celgene by 2.8% in the 4th quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock worth $3,438,486,000 after acquiring an additional 1,459,100 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Celgene by 9,691.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 16,327,522 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Celgene by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 9,942,267 shares of the biopharmaceutical company’s stock valued at $636,179,000 after buying an additional 787,638 shares in the last quarter. Norges Bank bought a new stake in Celgene during the 4th quarter valued at about $484,390,000. Finally, Clearbridge Investments LLC lifted its holdings in Celgene by 9.2% during the 3rd quarter. Clearbridge Investments LLC now owns 7,133,588 shares of the biopharmaceutical company’s stock valued at $638,385,000 after buying an additional 598,631 shares in the last quarter. Institutional investors and hedge funds own 72.01% of the company’s stock.
Shares of CELG stock traded up $0.04 during trading hours on Friday, hitting $95.51. The company’s stock had a trading volume of 4,976,019 shares, compared to its average volume of 5,989,271. The company has a market capitalization of $67.36 billion, a P/E ratio of 12.55, a price-to-earnings-growth ratio of 0.44 and a beta of 1.68. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $97.07.
A number of equities research analysts recently weighed in on CELG shares. Zacks Investment Research upgraded shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 price objective for the company in a report on Wednesday, January 23rd. Cantor Fitzgerald restated a “buy” rating and issued a $100.00 price target on shares of Celgene in a report on Thursday, January 31st. Jefferies Financial Group lowered shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a report on Friday, February 1st. Cowen started coverage on shares of Celgene in a report on Tuesday, February 26th. They issued a “market perform” rating and a $102.00 price target for the company. Finally, William Blair reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, February 28th. Twenty investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $95.96.
In related news, Director Ernest Mario acquired 2,000 shares of Celgene stock in a transaction on Tuesday, February 12th. The stock was bought at an average cost of $89.99 per share, for a total transaction of $179,980.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.39% of the company’s stock.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.